Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Solid Tumor × MEK inhibitor I × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1

Conditions

Solid Tumor, Adult 1 Solid Tumor 1

Interventions

Injections 11 pembrolizumab 9 Paclitaxel 8 senaparib 7 Docetaxel 7 Nivolumab 6 Cisplatin 5 Capecitabine 5 toripalimab 4 atezolizumab 4 Ipilimumab 4 Gemcitabine 4 tislelizumab 3 Rifampin 3 Itraconazole 3 Carboplatin 3 Bevacizumab 3 130-nm albumin-bound paclitaxel 3 zimberelimab 2 sintilimab 2 pertuzumab 2 ontuxizumab 2 magrolimab 2 fluzoparib 2 famitinib 2 durvalumab 2 camrelizumab 2 alpha-Synuclein 2 Oxaliplatin 2 Midazolam 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02968485 2019-01-15

Phase I Study of SHR7390 in Patients With Advanced Solid Tumors

Jiangsu HengRui Medicine Co., Ltd.

Phase 1 Unknown

Other solid neoplasm

Solid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon ⚡